Where do you get that number. I see no willful infringement but lost damages valid. Was there enough lost business according to the allowed testimony of Masi's expert to get that #?
Investing 101. Shorts are just fuel for the fire, once the trend changes(as now). A short squeeze is a wonderful thing to watch on an illiquid security.
They have controlled stock the last few days but that's about to change. 10 millions shares will have a tough time covering on this illiquid stock.
Pending contracts as every hospital in America will be forced to have protective suits at the ready.
This form by Beecher was done as a grant and was listed as such in the transaction code section. It has been my experience that most of these forms would make a verbal explanation under the "remarks section"; but vaso does not chose to do this. But, my mistake. No buy but a "properly coded" grant.
Party on vaso. Free stock for everyone(but us shareholders.
There is no reason for this company to have remained near year highs while the market has been so volatile. There are very few small players left in this sector. Buy out in progress.......
The analyst estimates that peak U.S. sales for Cynapsus’s thin film strip apomorphine product, APL-130277, will be about $300-million. Applying the same multiple that Acorda paid for Citivias, which was 1.05 sales, implies a $315-million takeout, or $2.18 per share, points out Pearlstein. He expects this might happen in six to eight months, after the results of CTH-300a, double-blind, placebo-controlled, parallel-design study with Parkinson’s patients who have at least one “off” episode every 24 hours, with total “off” time of at least 2 hours, are made available.
In a research update to clients Friday, Pearlstein maintained his “Buy” rating and $1.75 one-year target on Cynapsus Therapeutics, implying a return of 182% at the time of publication
Filed today for a transaction done on 9/26/14. The form appears to show an open market purchase of 125,000 shares at .19. This gives him almost 500k shares.
If this were an open market purchase it would be super bullish but total volume for that day was only 55,000 shares, so that would be impossible. The last form 4 by Beecher was filed in correctly(as it appears this one is) as an open market purchase also.
I can give vaso's legal team a pass on incorrectly filing the first form 4 a while back, but the fact that they continue to file incorrectly can only lead one to believe that they are purposely trying to deceive investors and shareholders here.
This is IMHO a 4 related to stock grant but 4 does not show that. Vaso's lawyer is our buddy Leiberman, who has been paid handsomely over the years in company stock. Does he not understand what form he should file and what info should be on form????????????????
Can this friggin company do anything right?
Multi 1000 contract bull spead put on 2 days before decision.
bought oct 5 call at 1.2
sold oct 7 1/2 at .37
Cost ,83 stock price 5.83
max profit at 7 1/2.........1.67.............that's where stock is headed is short time frame(oct exp)
broader label ILUVIEN has been granted by the FDA," said Dan Myers, president and chief executive officer of Alimera
That's what will sink the shorts.